NVAX Stock: Price, Earnings History and SEC Filings
Novavax, Inc. (NVAX) last traded at $10.08, down 3.72% on the latest session and down 6.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.32 against an analyst estimate of $-0.36, a beat of 11.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NVAX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.32 | $-0.36 | +11.11% |
| Mar 2026 | May 6, 2026 | $-0.06 | $-0.25 | +76.00% |
| Dec 2025 | Feb 26, 2026 | $0.11 | $-0.66 | +116.67% |
| Sep 2025 | Nov 6, 2025 | $-0.62 | $-1.08 | +42.59% |
NVAX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How NVAX reacts to earnings
Across its last 8 earnings releases, NVAX moved 8.7% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +0.52% |
| 2026-05-06 | Before open | +15.56% |
| 2026-02-26 | Before open | +17.42% |
| 2026-01-12 | Before open | +6.60% |
| 2025-11-06 | Before open | -1.30% |
| 2025-08-06 | Before open | +12.63% |
| 2025-05-08 | Before open | +11.93% |
| 2025-02-27 | Before open | -3.55% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NVAX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.1B | $440M | – | 39.2% | $2.58 |
| 2024 | $682M | -$187M | – | -27.5% | $-1.23 |
| 2023 | $984M | -$545M | – | -55.4% | $-5.41 |
| 2022 | $2.0B | -$658M | – | -33.2% | $-8.42 |
| 2021 | $1.1B | -$1.7B | – | -152.1% | $-23.44 |
| 2020 | $476M | -$418M | – | -87.9% | $-7.27 |
| 2019 | $19M | -$133M | – | -711.0% | $-5.51 |
| 2018 | $34M | -$185M | – | -538.8% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NVAX
- 8-K · Oct 29, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Jun 23, 2026Shareholder vote
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 6, 2026
- DEF 14A · Apr 27, 2026
- 8-K · Feb 26, 2026Results of operations, Financial statements and exhibits
- 10-K · Feb 26, 2026
- 8-K · Jan 20, 2026Material agreement
Insider filing activity
NVAX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NVAX news
- Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeOct 29, 2026 · finance.yahoo.com
- Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026Oct 29, 2026 · finance.yahoo.com
- Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherOct 28, 2026 · 247wallst.com
- Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowOct 26, 2026 · finance.yahoo.com
- What Novavax Doubters OverlookedOct 24, 2026 · finance.yahoo.com
- 3 small-cap stocks walking a fine lineOct 23, 2026 · finance.yahoo.com
- Is Novavax (NVAX) Fully Priced Relative To Its Sales Base?Oct 23, 2026 · finance.yahoo.com
About Novavax, Inc.
Novavax, Inc. (NVAX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.